• 1. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperazinoazepines Piperazinoazepines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperazinoazepines

Mirtazapine-d: A Comprehensive Overview

Mirtazapine-d, also known by its CAS number 1216678-68-0, is a compound of significant interest in the field of pharmaceutical research and development. This compound has garnered attention due to its unique properties and potential applications in various therapeutic areas. In this article, we will delve into the details of Mirtazapine-d, exploring its chemical structure, pharmacological properties, and the latest research findings that highlight its potential in modern medicine.

The chemical structure of Mirtazapine-d is a derivative of mirtazapine, a well-known antidepressant. Mirtazapine itself is classified as a tetracyclic antidepressant (TeCAs) and works by inhibiting the reuptake of norepinephrine and serotonin, thereby enhancing their levels in the brain. The "d" in Mirtazapine-d signifies a deuterated version of the compound, where certain hydrogen atoms are replaced with deuterium atoms. This modification can have significant implications for the compound's stability, pharmacokinetics, and bioavailability.

Recent studies have shown that deuterated compounds like Mirtazapine-d can exhibit improved pharmacokinetic profiles compared to their non-deuterated counterparts. Deuterium substitution can reduce the rate of metabolism by cytochrome P450 enzymes, potentially leading to longer half-lives and reduced dosing frequency. This makes Mirtazapine-d an attractive candidate for developing sustained-release formulations or for use in conditions where prolonged drug action is desirable.

In terms of pharmacological activity, Mirtazapine-d has been investigated for its potential as an antidepressant. Preclinical studies suggest that it retains the core antidepressant properties of mirtazapine while potentially offering enhanced efficacy and reduced side effects due to its modified metabolic profile. Additionally, research into its mechanism of action has revealed that it interacts with multiple neurotransmitter systems, including dopamine and histamine receptors, which may contribute to its broad therapeutic potential.

One area of particular interest is the exploration of Mirtazapine-d in the treatment of treatment-resistant depression (TRD). Traditional antidepressants often fail to provide adequate relief for patients with TRD, making novel approaches essential. Early-stage clinical trials have indicated that Mirtazapine-d may offer a safer and more effective alternative for these patients, with fewer adverse effects such as sedation or weight gain.

Beyond its antidepressant properties, recent research has also explored the potential of Mirtazapine-d in other therapeutic areas. For instance, studies have suggested that it may have neuroprotective effects, making it a candidate for treating neurodegenerative disorders such as Alzheimer's disease or Parkinson's disease. Its ability to modulate multiple neurotransmitter systems could be particularly beneficial in these conditions, where a multifaceted approach to treatment is often required.

Another promising avenue for Mirtazapine-d is its potential use in pain management. Preclinical models have shown that it may possess analgesic properties, particularly in chronic pain conditions such as neuropathic pain or inflammatory pain. This could make it a valuable addition to the arsenal of treatments available for patients suffering from chronic pain syndromes.

The development of Mirtazapine-d has also been influenced by advancements in drug delivery systems. Researchers are exploring innovative ways to enhance its bioavailability and reduce any potential side effects through targeted delivery mechanisms such as nanoparticles or liposomal encapsulation. These approaches could further enhance the therapeutic potential of Mirtazapine-d and pave the way for more effective treatments across various indications.

Looking ahead, the future of Mirtazapine-d appears bright as ongoing research continues to uncover new insights into its pharmacological properties and therapeutic applications. Its deuterated nature offers unique advantages that could set it apart from existing treatments, making it a compelling option for addressing unmet medical needs in psychiatry and neurology.

In conclusion, Mirtazapine-d (CAS No. 1216678-68-0) represents a promising advancement in pharmaceutical science with diverse applications across multiple therapeutic areas. As research progresses and clinical data continues to emerge, this compound has the potential to become an essential tool in the treatment of various conditions, offering improved efficacy and safety profiles compared to current therapies.

• 85650-52-8(Mirtazapine)
• 61337-68-6(Desmethylmirtazapine)
• 78253-61-9(2-(piperidin-1-yl)pyridine-3-carboxylic acid)
• 61337-67-5(Mirtazapine)
• 61337-89-1(2-(4-Methyl-2-phenyl-1-piperazinyl)-3-pyridinemethanol)
• 41218-84-2((6,11-Dihydro-5H-dibenzob,eazepin-6-yl)methanamine)
• 61364-37-2((7R)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,?.0?,13]nonadeca-1(19),8,10,12,15,17-hexaene)
• 5654-97-7(1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one)
• 61337-87-9(S-Mirtazapine)
• 191546-94-8(4-Methyl-1-(3-methyl-2-pyridinyl)-2-phenylpiperazine)